Multiple Sclerosis and Neuroimmunology Clinical Trials

Project BIG: The Stanford Brain Immune Gut Research Initiative
Status: Active, Enrolling
PI: Jeffrey Dunn, MD
Research Coordinator: Anna Tomczak
Contact: atomc96@stanford.edu

A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (BEAT-MS-ITN077AI)
PI: Jeffrey Dunn, MD
NCT04047628
Status: Active, Enrolling
Research Coordinator: Sujatha Kalle
Contact: skalle@stanford.edu

A multiple-center, non-randomized, open-label, adaptive, single ascending dose, Phase I Study to investigate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of RO7121932 following intravenous administration in patients with Multiple Sclerosis
PI: May Han, MD
Study Status: Active, Enrolling
Research Coordinator: Sujatha Kalle
Contact: skalle@stanford.edu

A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis (BN42083)
PI: Lucas Kipp, MD
NCT04548999
Study Status: Active, Enrolling
Research Coordinator: Julia Sumera
Contact: jsumera@stanford.edu

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis (GN42272)
PI: Lucas Kipp, MD
NCT04586023
Study Status: Active, Enrolling
Research Coordinator: Julia Sumera
Contact: jsumera@stanford.edu

North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) Study
PI: Jeffrey Dunn, MD
Study Status: Active, Enrolling
Research Coordinator: Anna Tomczak
Contact: atomc96@stanford.edu

CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
PI: May Han, MD
Study Status: Active, Enrolling
Research Coordinator: Anna Tomczak
Contact: atomc96@stanford.edu

A randomized, double-blind, placebo-controlled, multicenter, Phase 3, pivotal study with an open-label extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD)
PI: May Han, MD
NCT05063162
Study Status: Active, Enrolling
Research Coordinator: Tara Tripathi Sarkar
Contact: tarats@stanford.edu

High Dimensional Analysis of Immune Subsets with Mass Cytometry and Multiparameter Flow Cytometry in Patients with Secondary Progressive Multiple Sclerosis Treated with Siponimod
PI: Lawrence Steinman, MD
Study Status: Active, Enrolling
Research Coordinator: Anna Tomczak
Contact: atomc96@stanford.edu

A Phase 1, Double-blind, Placebo-controlled Dose-expansion Study with an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis (ATA188)
PI: Lawrence Steinman, MD
Study Status: Closed to Enrollment
Research Coordinator: Anna Tomczak
Contact: atomc96@stanford.edu

A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis (BN42082)
PI: Lucas Kipp, MD
NCT04544436
Study Status: Closed to Enrollment
Research Coordinator: Julia Sumera
Contact: jsumera@stanford.edu

A Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif ®) in Patients with Relapsing Multiple Sclerosis
PI:  Jeffrey Dunn, MD
NCT01412333
Study Status: Closed to Enrollment
Research Coordinator: Yamuna Joseph

An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis
PI: Christopher Lock, MD
NCT02688985
Study Status: Closed to Enrollment
Research Coordinator: Yamuna Joseph